Search results for "Lip"

showing 10 items of 8306 documents

Is diabetes the cost to pay for a greater cardiovascular prevention?

2010

The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites,…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthDiabete2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansRosuvastatinRisk factorRosuvastatin CalciumAdverse effectGlycemicSulfonamidesbusiness.industryPreventionIncidence (epidemiology)Statinsnutritional and metabolic diseasesCardiovascular riskmedicine.diseaseFluorobenzenesRosuvastatin CalciumEndocrinologyPyrimidineschemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)Glycated hemoglobinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes ?

2009

Ezetimibe represents the first of a new class of agents, the cholesterol absorption inhibitors, able to reduce low-density lipoproteins (LDL)-cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. To-date all the data regarding the efficacy of ezetimibe comes from the studies of its lipid-lowering power. Yet, recent findings from the ENHANCE study on atherosclerosis progression showed that the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolemia did not affect the mean change in carotid intima-media thickness, although a significant reduction in LDL-cholesterol levels was present. Therefore, we cannot exclude that e…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthFamilial hypercholesterolemiaBioinformatics2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundEzetimibePredictive Value of TestsInternal medicinemedicineAnimalsHumansProspective cohort studyCardiovascular risk Cholesterol LDL size Small dense LDLDyslipidemiasEzetimibe LDL-cholesterolCholesterolVascular diseasebusiness.industryAnticholesteremic AgentsHypertriglyceridemiaReproducibility of ResultsCholesterol LDLEzetimibemedicine.diseaseTreatment OutcomeEndocrinologychemistrySimvastatinAzetidinesDrug Therapy Combinationlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersDyslipidemiamedicine.drug
researchProduct

Atherogenic dyslipidemia and oxidative stress: a new look

2009

Although results from in vitro studies and clinical trials demonstrate strong associations between oxidative stress and cardiovascular risk, to date still no convincing data are available to suggest that treatment with antioxidants might reduce vascular events. Oxidative modifications of low-density lipoproteins (LDL) represent an early stage of atherosclerosis, and small, dense LDL are more susceptible to oxidation than larger, more buoyant particles. Oxidized LDL are independent predictors of subclinical and clinical atherosclerosis. Recent studies suggested that novel therapeutic strategies may take into account the removal of such particles from circulation. Future research is required …

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthOxidative phosphorylation030204 cardiovascular system & hematology2704 Biochemistry (medical)medicine.disease_causeAtherogenic dyslipidemia oxidative stressCoronary artery disease03 medical and health sciences2737 Physiology (medical)0302 clinical medicinePhysiology (medical)Internal medicineHumansMedicineDyslipidemias030304 developmental biologySubclinical infectionchemistry.chemical_classification0303 health sciencesReactive oxygen speciesAtherogenic dyslipidemiabusiness.industryVascular diseaseBiochemistry (medical)Public Health Environmental and Occupational HealthAtherogenic dyslipidemia2739 Public Health Environmental and Occupational HealthGeneral MedicineAtherosclerosismedicine.disease3. Good healthLipoproteins LDLOxidative StressEndocrinologychemistrybusinessOxidized ldlOxidative stressTranslational Research
researchProduct

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

2008

Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins. Thiazolidindiones are able to lower the levels of fasting glucose and glycated hemoglobin significantly by improving insulin sensitivity, as well as improving some aspects of diabetic dyslipidemia: total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol tend to increase while triglycerides are generally decreased.This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on sma…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicine2736 Pharmacology (medical)HumansHypoglycemic AgentsPharmacology (medical)Clinical significancecardiovascular risk dense low-density lipoprotein diabetes low-density lipoprotein size pioglitazone rosiglitazone smallTriglyceridesDyslipidemiasPharmacologyAtherogenic dyslipidemiaPioglitazonebusiness.industryThiazolidindionesAtherogenic dyslipidemiaGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinology3004 PharmacologychemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)ThiazolidinedionesGlycated hemoglobinbusinessRosiglitazoneLipoproteins HDLPioglitazoneBiomarkersmedicine.drugLipoprotein
researchProduct

Clearance and metabolism of arachidonic acid by C6 glioma cells and astrocytes.

1995

Effects of increased levels of arachidonic acid (AA) were analyzed in vitro by employment of C6 glioma cells and astrocytes from primary culture. The cells were suspended in a physiological medium added with arachidonic acid (AA) in a concentration range from 0.01 to 0.5 mM. The concentration profiles of the fatty acid and AA-metabolites were subsequently followed for 90 min. AA was measured by gas chromatography, whereas the AA-metabolites PGF2 alpha and LTB4 by radioimmunoassay (RIA). Following administration of AA at 0.05 or 0.1 mM the medium was completely cleared from the fatty acid within 10 to 15 min. However, when 0.5 mM were added, AA concentrations of 0.36 +/- 0.055 mM were found …

medicine.medical_specialty45-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amineBiologyDinoprostBiochemistryLeukotriene B4Cellular and Molecular NeuroscienceLipoxygenasechemistry.chemical_compoundInternal medicinemedicineTumor Cells CulturedCyclooxygenase InhibitorsLipoxygenase Inhibitorschemistry.chemical_classificationArachidonic AcidFatty acidRadioimmunoassayGeneral MedicineMetabolismGliomaCulture MediaKineticsEndocrinologymedicine.anatomical_structurechemistryCell cultureAstrocytesbiology.proteinNeurogliaArachidonic acidAstrocyteNeurochemical research
researchProduct

Endoscopic Resection of a Large Colonic Lipoma: Case Report and Review of Literature

2010

Colonic lipomas are uncommon, benign, submucosal adipose tumors that are usually asymptomatic. Large lipomas can cause symptoms such as constipation, abdominal pain, rectal bleeding and intussusception. We report the case of a 60-year-old man with a history of lower abdominal pain and pseudoobstructive symptoms. Colonoscopy revealed a large polypoid sessile lesion in the sigma. We used a standardized technique of polypectomy, preceded by submucosal injection of dilute 5 ml polygelin with epinephrine 1:10,000 solution, to fully resect large colonic lipomas. The lipoma size was 3.5 cm. No bleeding or perforation developed. Histology showed the polyp to be a submucosul lipoma. On follow-up, th…

medicine.medical_specialtyAbdominal painendoscopic resection.medicine.medical_treatmentPerforation (oil well)ColonoscopyColonic lipomaLesionIntussusception (medical disorder)medicineotorhinolaryngologic diseaseslcsh:RC799-869Literature reviewSessile Lesionmedicine.diagnostic_testcolonbusiness.industryGastroenterologyLipomamedicine.diseasePolypectomySurgeryPublished: February 2010body regionsSettore MED/18 - Chirurgia Generalestomatognathic diseasesEndoscopic resectionlcsh:Diseases of the digestive system. GastroenterologyLipomamedicine.symptombusinessCase Reports in Gastroenterology
researchProduct

IVIG in APS pregnancy

2004

For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as ‘IVIG’) has benefited patients with a variety of autoimmune disorders. A potential therapeutic role of IVIG in the prevention of thrombosis and of miscarriages in antiphospholipid syndrome (APS) has been postulated. Multicenter randomized controlled trials attempted to define the role of IVIG in preventing pregnancy complications in APS indicate that simple anticoagulation could not be completely satisfactory, and certain patient subgroups might take advantage of IVIG therapy alone or in combination with heparin.

medicine.medical_specialtyAbortion Habitual030204 cardiovascular system & hematologyrecurrent fetal losslaw.invention03 medical and health sciences0302 clinical medicineRheumatologyRandomized controlled trialAntiphospholipid syndromelawPregnancyhemic and lymphatic diseasesInternal medicinemedicineHigh dosesHumans030203 arthritis & rheumatologyIVIGPregnancybiologybusiness.industryPregnancy Complications HematologicImmunoglobulins IntravenousThrombosisHeparinmedicine.diseaseAntiphospholipid SyndromeThrombosisPregnancy ComplicationsImmune Globulin TherapyImmunologybiology.proteinFemaleAntibodybusinessmedicine.drugAPS
researchProduct

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

2020

AbstractHemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The…

medicine.medical_specialtyAcetylgalactosamineInjections SubcutaneousLipoproteinsHemorrhage030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedHemophilia AHemophilia BSeverity of Illness IndexDisease courseFactor IX03 medical and health sciencesRoute of administrationLife Expectancy0302 clinical medicineAntibodies BispecificmedicineHumansRNA Small InterferingInfusions IntravenousIntensive care medicineFactor IXClotting factorClinical Trials as TopicFactor VIIICoagulantsbusiness.industryGenetic TherapyHematologyIntravenous InfusionsHistory 20th CenturyBlood Coagulation FactorsLaboratoriesbusiness030215 immunologymedicine.drugHämostaseologie
researchProduct

Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease

2006

Abstract Background Sphingomyelin (SM) is the major phospholipid in cell membranes and in lipoproteins. In human plasma, SM is mainly found in atherogenic lipoproteins; thus, high levels of SM may promote atherogenesis. Methods We investigated in a median follow up of 6.0 years the association of SM with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) in stable and unstable patients, and its relation to other marker of atherosclerosis in 1,102 patients with angiographically documented CAD and 444 healthy controls. Results and discussion Logistic regression analysis showed that SM categorized by median was associated with an elevated risk for CAD (HR 3.2…

medicine.medical_specialtyAcute coronary syndromeApolipoprotein BEndocrinology Diabetes and MetabolismMedicine (miscellaneous)lcsh:TX341-641Clinical nutritionGastroenterologyCoronary artery diseasechemistry.chemical_compoundMedian follow-upInternal medicinemedicineMyocardial infarctionRisk factorlcsh:RC620-627Nutrition and DieteticsTriglyceridebiologybusiness.industryResearchmedicine.diseaselcsh:Nutritional diseases. Deficiency diseasesEndocrinologychemistrybiology.proteinbusinesslcsh:Nutrition. Foods and food supplyNutrition & Metabolism
researchProduct

Tumors of the labial mucosa: a retrospective study of 1045 biopsies

2020

Background To investigate the relative frequency of localized mucosal swellings of the upper and lower labial mucosa, the clinical-pathological diagnosis agreement and whether patient’s age and gender and tumor’s site and size may raise the suspicion of neoplasm. Material and Methods Retrospective analysis was performed on upper or lower labial mucosal tumors, histopathologically diagnosed between 2009-2018. The diagnostic categories developmental/reactive tumors, benign and malignant neoplasms were associated with patient’s age and gender and tumor’s site and size; clinical-pathological diagnosis agreement was, also, evaluated. Results Overall, 1000 (95.7%) developmental/reactive tumors, 3…

medicine.medical_specialtyAdenomainflammatory mediatorsBiopsyLower lipelderlyGastroenterologyInternal medicinemedicineNeoplasmHumansLabial MucosaperiodontitisGeneral DentistryPathologicalUNESCO:CIENCIAS MÉDICASRetrospective StudiesOral Medicine and Pathologybusiness.industryResearchneurodegenerationUpper lipMouth MucosaRetrospective cohort studyLipomamedicine.diseaseLipstomatognathic diseasesOtorhinolaryngologyLip Neoplasmsalzheimer´s diseaseSurgerybusinessMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct